In a recent case report, canagliflozin is suspected to be the culprit of rosuvastatin myotoxicity. What is the theorized mechanism of this potential drug interaction?
In a recent case report, it is theorized that canagliflozin enhanced the absorption of rosuvastatin and inhibited both biliary and renal elimination through inhibition of the efflux transporter Brease Cancer Resistance Protein (BCRP).
Brailovski E et al. Rosuvastatin Myotoxicity After Starting Canagliglozin Treatment: A Case Report. Ann Intern Med 2020; published online 4 August 2020. https://doi.org/10.7326/L20-0549